Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.837
-0.024 (-2.81%)
At close: Apr 28, 2026, 4:00 PM EDT
0.837
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Aprea Therapeutics Revenue
In the year 2025, Aprea Therapeutics had annual revenue of $285.76K, down -80.98%. Aprea Therapeutics had revenue of $3.34K in the quarter ending December 31, 2025, a decrease of -98.38%.
Revenue (ttm)
$285.76K
Revenue Growth
-80.98%
P/S Ratio
33.54
Revenue / Employee
$35,720
Employees
8
Market Cap
9.58M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPRE News
- 7 days ago - Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - GlobeNewsWire
- 27 days ago - Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - GlobeNewsWire
- 4 weeks ago - Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement - GlobeNewsWire
- 4 weeks ago - Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - GlobeNewsWire
- 6 weeks ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
- 2 months ago - Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - GlobeNewsWire